IBTA vs REGN · rev $367.3M vs P/E 14, rev $14.34B
Ibotta, Inc. (IBTA) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ibotta, Inc. (IBTA) is a software - application company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported IBTA revenue for 2024-12-31 was $367.3M. Net income was $68.7M. Revenue was up 14.8% from 2023-12-31 to 2024-12-31. IBTA currently screens at market cap $764.6M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
IBTA currently screens at market cap $764.6M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the IBTA and REGN stock pages for the full models.
Not investment advice.